about
Developing stem cell therapies for juvenile and adult-onset Huntington's diseaseChorea: A Journey through HistoryA dynamic structural model of expanded RNA CAG repeats: a refined X-ray structure and computational investigations using molecular dynamics and umbrella sampling simulations.Computational investigation of RNA CUG repeats responsible for myotonic dystrophy 1Neurological Disorders Associated with Striatal Lesions: Classification and Diagnostic Approach.Use of Genetically Altered Stem Cells for the Treatment of Huntington's Disease.Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.Glucose transporter 3 is a rab11-dependent trafficking cargo and its transport to the cell surface is reduced in neurons of CAG140 Huntington's disease miceAbnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse modelsCause or Effect: Misregulation of microRNA Pathways in Neurodegeneration.Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits.The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis.Glial epigenetics in neuroinflammation and neurodegeneration.Polyglutamine (PolyQ) diseases: genetics to treatments.The pig as an animal model for human pathologies: A proteomics perspective.Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders.Validation of a prognostic index for Huntington's disease.MicroRNAs in glaucoma and neurodegenerative diseases.Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain.Taking a break from huntingtin.Taking a break from huntingtin.Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).Huntington's Disease (HD): Neurodegeneration of Brodmann's Primary Visual Area 17 (BA17).Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.Age-related length variability of polymorphic CAG repeats.
P2860
Q26799722-9CED1468-6D0F-4454-905A-336D2A31B24DQ27002634-B939F9D4-66A2-4FAF-8304-61FB6E971FF9Q27676633-BD5C2DDE-828D-49FB-A00C-FFEB6861B920Q30668605-F04D577D-A399-41BD-8DBC-77198D696E23Q31076462-B2E971D7-5857-4DA1-8DFA-7C5EE6CFEB18Q33788929-FB2A3CCF-E811-4F64-9F8C-E2265DB870A1Q34162629-C5C0DE1E-7A03-4B30-AC61-F774BF8E6FE2Q34979045-ED56260C-959B-4B69-9579-A5F8931844C6Q35688598-286C919A-4DF9-4A20-AA14-B07A8EFDD69EQ35875886-EFF5DE6A-2A68-46B5-BDEB-2A395FFFE5A9Q37999105-BFE2A0B8-01E0-4ACA-BC22-B8F8B3799921Q38018281-02C58C0A-0D75-4FDC-9497-6361EF29CAA5Q38197952-89EC1FA6-0718-4B2C-8766-42F838DE4680Q38210865-B38A4439-99F4-4C7D-85E2-F92271954150Q38237026-C290646E-CBF6-4551-A561-9BF1B283ABCEQ38530085-507F2018-C6BE-4490-A8C9-0C173883E157Q38790095-AEC51EE2-4381-497C-9F1E-6AF7F917C612Q38895922-D73F7B22-DAB3-4560-89EC-3E66668EA754Q39193175-845E8D0D-1344-40CB-8EC5-B14D0833D348Q41834318-C279DD81-95B5-467D-A515-41103057DF50Q42324308-FEB31138-30BE-4D40-8501-AC3BB7049C43Q45298405-935D57CC-56C6-429C-ADD4-0202E1DA7F22Q45303234-F7A9B0F7-AFB6-4BD1-B46D-D51091F30FBCQ45304705-3A0C67A1-16E4-43CA-8AEE-E43AFDA61875Q48423508-4544BA60-A7E8-4224-A37E-575D1E1544C3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Milestones in huntington disease.
@en
Milestones in huntington disease.
@nl
type
label
Milestones in huntington disease.
@en
Milestones in huntington disease.
@nl
prefLabel
Milestones in huntington disease.
@en
Milestones in huntington disease.
@nl
P2860
P356
P1433
P1476
Milestones in huntington disease.
@en
P2093
Anne B Young
Ira Shoulson
P2860
P304
P356
10.1002/MDS.23685
P407
P577
2011-05-01T00:00:00Z